The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom

Shinichiro Okata, Shinsuke Yuasa, Teiichi Yamane, Tetsushi Furukawa, Keiichi Fukuda

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The long QT syndrome type 2 (LQT2) is inheritable life threatening arrhythmic disorder and one of the most common genetic variants in long QT syndrome. There are some indications for treatment of the patients with LQT2 but it is impossible to completely prevent fatal arrhythmia. To develop novel therapy for the patients with LQT2, it has been desired to generate diseasespecific and patient-specific disease model. Human induced pluripotent stem (iPS) cells are somatic cell-derived pluripotent stem cells with infinite proliferation ability and multipotency. Patient-specific iPS cells can be derived from patient somatic cells, have all genomic information encoded in patient's genome including mutation and all SNPs, and can be ideal disease models of the patients. To generate disease model for LQT2 by iPS cells, we should firstly generate iPS cells from the patient with LQT2 and confirm the genomic mutation in iPS cells. In this study, we showed the successful generation of iPS cells from a patient with KCNH2 G603D mutation. The patient specific iPS cells properly expressed stem cell markers, such as NANOG and OCT3/4. We also confirmed that the KCNH2 G603D (G1808A) mutation was taken over in patient specific iPS cells. These patient-specific iPS cells may contribute to the future analysis for disease pathogenesis and drug innovation.

Original languageEnglish
Pages (from-to)17-22
Number of pages6
JournalJournal of Medical and Dental Sciences
Volume60
Issue number1
Publication statusPublished - 2013

Fingerprint

Long QT Syndrome
Induced Pluripotent Stem Cells
Mutation
Pluripotent Stem Cells
Single Nucleotide Polymorphism
Cardiac Arrhythmias
Stem Cells

Keywords

  • Disease modeling
  • iPS cell
  • Long QT syndrome

ASJC Scopus subject areas

  • Dentistry(all)
  • Medicine(all)

Cite this

The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom. / Okata, Shinichiro; Yuasa, Shinsuke; Yamane, Teiichi; Furukawa, Tetsushi; Fukuda, Keiichi.

In: Journal of Medical and Dental Sciences, Vol. 60, No. 1, 2013, p. 17-22.

Research output: Contribution to journalArticle

@article{b337b0f654b54cd7b8e97619e5fe51ec,
title = "The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom",
abstract = "The long QT syndrome type 2 (LQT2) is inheritable life threatening arrhythmic disorder and one of the most common genetic variants in long QT syndrome. There are some indications for treatment of the patients with LQT2 but it is impossible to completely prevent fatal arrhythmia. To develop novel therapy for the patients with LQT2, it has been desired to generate diseasespecific and patient-specific disease model. Human induced pluripotent stem (iPS) cells are somatic cell-derived pluripotent stem cells with infinite proliferation ability and multipotency. Patient-specific iPS cells can be derived from patient somatic cells, have all genomic information encoded in patient's genome including mutation and all SNPs, and can be ideal disease models of the patients. To generate disease model for LQT2 by iPS cells, we should firstly generate iPS cells from the patient with LQT2 and confirm the genomic mutation in iPS cells. In this study, we showed the successful generation of iPS cells from a patient with KCNH2 G603D mutation. The patient specific iPS cells properly expressed stem cell markers, such as NANOG and OCT3/4. We also confirmed that the KCNH2 G603D (G1808A) mutation was taken over in patient specific iPS cells. These patient-specific iPS cells may contribute to the future analysis for disease pathogenesis and drug innovation.",
keywords = "Disease modeling, iPS cell, Long QT syndrome",
author = "Shinichiro Okata and Shinsuke Yuasa and Teiichi Yamane and Tetsushi Furukawa and Keiichi Fukuda",
year = "2013",
language = "English",
volume = "60",
pages = "17--22",
journal = "Journal of Medical and Dental Sciences",
issn = "1342-8810",
publisher = "Tokyo Medical and Dental University",
number = "1",

}

TY - JOUR

T1 - The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom

AU - Okata, Shinichiro

AU - Yuasa, Shinsuke

AU - Yamane, Teiichi

AU - Furukawa, Tetsushi

AU - Fukuda, Keiichi

PY - 2013

Y1 - 2013

N2 - The long QT syndrome type 2 (LQT2) is inheritable life threatening arrhythmic disorder and one of the most common genetic variants in long QT syndrome. There are some indications for treatment of the patients with LQT2 but it is impossible to completely prevent fatal arrhythmia. To develop novel therapy for the patients with LQT2, it has been desired to generate diseasespecific and patient-specific disease model. Human induced pluripotent stem (iPS) cells are somatic cell-derived pluripotent stem cells with infinite proliferation ability and multipotency. Patient-specific iPS cells can be derived from patient somatic cells, have all genomic information encoded in patient's genome including mutation and all SNPs, and can be ideal disease models of the patients. To generate disease model for LQT2 by iPS cells, we should firstly generate iPS cells from the patient with LQT2 and confirm the genomic mutation in iPS cells. In this study, we showed the successful generation of iPS cells from a patient with KCNH2 G603D mutation. The patient specific iPS cells properly expressed stem cell markers, such as NANOG and OCT3/4. We also confirmed that the KCNH2 G603D (G1808A) mutation was taken over in patient specific iPS cells. These patient-specific iPS cells may contribute to the future analysis for disease pathogenesis and drug innovation.

AB - The long QT syndrome type 2 (LQT2) is inheritable life threatening arrhythmic disorder and one of the most common genetic variants in long QT syndrome. There are some indications for treatment of the patients with LQT2 but it is impossible to completely prevent fatal arrhythmia. To develop novel therapy for the patients with LQT2, it has been desired to generate diseasespecific and patient-specific disease model. Human induced pluripotent stem (iPS) cells are somatic cell-derived pluripotent stem cells with infinite proliferation ability and multipotency. Patient-specific iPS cells can be derived from patient somatic cells, have all genomic information encoded in patient's genome including mutation and all SNPs, and can be ideal disease models of the patients. To generate disease model for LQT2 by iPS cells, we should firstly generate iPS cells from the patient with LQT2 and confirm the genomic mutation in iPS cells. In this study, we showed the successful generation of iPS cells from a patient with KCNH2 G603D mutation. The patient specific iPS cells properly expressed stem cell markers, such as NANOG and OCT3/4. We also confirmed that the KCNH2 G603D (G1808A) mutation was taken over in patient specific iPS cells. These patient-specific iPS cells may contribute to the future analysis for disease pathogenesis and drug innovation.

KW - Disease modeling

KW - iPS cell

KW - Long QT syndrome

UR - http://www.scopus.com/inward/record.url?scp=84875084211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875084211&partnerID=8YFLogxK

M3 - Article

C2 - 23917959

AN - SCOPUS:84875084211

VL - 60

SP - 17

EP - 22

JO - Journal of Medical and Dental Sciences

JF - Journal of Medical and Dental Sciences

SN - 1342-8810

IS - 1

ER -